読み込み中
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新データ
$0.3378
−$0.0922 · -21.44%
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
前日終値
$0.3378
−$0.0922 · -21.44%
日中の時刻はETです。市場データは遅延する場合があります。
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
日中レンジ
現在 $0.3378
52週レンジ
現在 $0.3378
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
54
適正価値
センチメント
58
まちまち
リスク
71
高リスク
モメンタム
17
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
日中レンジ
現在 $0.3378
52週レンジ
現在 $0.3378
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 3630.59万 USD | 3487.43万 USD | 2409.28万 USD | 434.56万 USD | 22.84万 USD |
| 売上原価 | 2438.23万 USD | 2420.45万 USD | 1575.36万 USD | 264.9万 USD | 11.78万 USD |
| 粗利益 | 1192.36万 USD | 1066.98万 USD | 833.92万 USD | 169.66万 USD | 11.06万 USD |
| 研究開発 | 60.43万 USD | 93.39万 USD | 185.58万 USD | 81.19万 USD | 67.22万 USD |
| 販売・一般管理 | 1962.66万 USD | 1493.75万 USD | 1082.98万 USD | 947.84万 USD | 186.58万 USD |
| 営業費用 | 1640.24万 USD | 1648.19万 USD | 1312.45万 USD | 1037.06万 USD | 255.07万 USD |
| 受取利息 | 28.09万 USD | 49.6万 USD | 81.2万 USD | 51.87万 USD | — |
| 支払利息 | — | 8774 USD | 13.73万 USD | 3.94万 USD | 32.88万 USD |
| 減価償却費と償却費 | 33.21万 USD | 22.35万 USD | 14.91万 USD | 2.52万 USD | 1.27万 USD |
| 営業利益 | −447.88万 USD | −581.21万 USD | −478.53万 USD | −867.4万 USD | −244.01万 USD |
| 純利益 | −597.54万 USD | −513.41万 USD | −450.6万 USD | −2674.44万 USD | −1243.64万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2026年6月1日 | 1:10 | — | — |
株式分割 | 2024年8月8日 | 1:20 | — | — |
株式分割 | 2024年4月17日 | 1:100 | — | — |
株式分割 | 2022年2月9日 | 1:200 | — | — |
株式分割 | 2020年4月6日 | 1:20 | — | — |
株式分割 | 2019年2月1日 | 1:20 | — | — |
発効済み 2026年6月1日
1:10
発効済み 2024年8月8日
1:20
発効済み 2024年4月17日
1:100
発効済み 2022年2月9日
1:200
発効済み 2020年4月6日
1:20
発効済み 2019年2月1日
1:20
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
